Table of Contents

Advancing IPF Diagnostics and Treatment Efforts with Collagen Hybridizing Peptides

At 3Helix, our research has delved into the utilization of Collagen Hybridizing Peptides (CHPs) to discern between inflamed and normal lung cells, mirroring the fibroblast dysfunction observed in idiopathic pulmonary fibrosis (IPF). The complexities of IPF pose large challenges in both its diagnosis and treatment. It is frequently identified at advanced stages of fibrosis or misdiagnosed altogether due to the vague and overlapping nature of its symptoms with other pulmonary conditions. Regrettably, available treatments slow fibrotic progression without addressing its root cause.

Our In Vivo CHPs are conjugated with sCy 7.5 for near-IR detection, and our B-CHP is conjugated with Biotin for Avidin/Streptavidin-mediated targeting.

Contact us for Customized Conjugates
Understanding Idiopathic Pulmonary Fibrosis (IPF)

Understanding nAMD

Introduction
Idiopathic Pulmonary Fibrosis (IPF) is an interstitial lung disease. It is characterized by relentless and progressive parenchymal fibrosis, and ventilatory restriction. IPF causes lung tissue to thicken and stiffen, usually leading to permanent scarring, breathing difficulties, a dry cough, and fatigue. No treatment can stop or reverse the scarring, but some medications help to slow the progression of IPF.
Current Treatment Challenges
Standard treatment for IPF includes antifibrotic drugs, oxygen therapy, pulmonary rehabilitation and lung transplantation. However, comorbidities such as pulmonary hypertension, lung cancer, and acute exacerbations can make treatment challenging. As of now, most clinical trials have failed to meet their primary endpoints, therefore there exists no treatment that successfully treats IPF -- the disease can only be slowed.
Why CHPs?
Our Collagen Hybridizing Peptides have shown striking differences of CHP uptake in dissected lungs of Bleomycin and normal mice. Such results are paving the pathway to an improved understanding of Idiopathic Pulmonary Fibrosis (IPF), serving as means to discover treatments and help those affected.